Diagnosis and treatment of hepatitis C virus (HCV) -related autoimmune features has become a clinical challenge in HCV-infected patients, in whom chronic liver disease associated with severe autoimmune features may contribute to a very poor prognosis. Both antiviral and immunosuppressive therapies, either alone or in combination, seem likely to have a key role. Based on the experience of mycophenolate mofetil (MMF) use in HCV patients receiving organ transplantation, this new immunosuppressive agent might represent a safe and effective therapeutic option to treat HCV-related extrahepatic features. Recent data are available for the use of MMF in HCV patients with autoimmune manifestations, mainly for autoimmune cytopenias and vasculitic features. MMF may be used as monotherapy or in association with other drugs for cases of HCV-related autoimmune diseases refractory or intolerant to common immunosuppressive treatments, allowing the reduction of the drug dosage and avoiding serious side effects.
European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial.Transplantation1999; 68: 391–396.
3.
ChanTM, LiFK, TangCS. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.N Engl J Med2000; 343: 1156–1162.
4.
LangfordCA, Talar-WilliamsC, SnellerMC.Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.Arthritis Rheum2004; 51: 278–283.
5.
KluppJ, GlanemannM, BechsteinWO. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.Transplant Proc1999; 31: 1113–1114.
6.
DiBisceglieAM, McHutchisonJ, RiceCM.New therapeutic strategies for hepatitis C.Hepatology2002; 35: 224–231.
7.
NeytsJ, MeerbachA, McKennaP, De ClercqE.Use of yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.Antiviral Res1996; 30: 125–132.
8.
EversonGT.Impact of immunosuppressive therapy on recurrence of hepatitis C.Liver Transpl2002; 8(Suppl 1): S19–S27.
9.
PattersonJL, Fernandez-LarsonR.Molecular action of ribavirin.Rev Infect Dis1990; 12: 1132–1146.
10.
FasolaCG, KlintmalmGB.Hepatitis C and mycophenolate mofetil - a clarification.Liver Transpl2002; 8: 411–412.
11.
PlatzKP, MuellerAR, WillimskiB. Indications for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation.Transpl Proc1998; 30: 1468–1469.
12.
OngJP, BarnesDS, YounossiZM. Outcome of de novo hepatitis C virus infection in heart transplant recipients.Hepatology1999; 30: 1293–1298.
13.
RostaingL, IzopetJ, SandresK, CisterneJM, PuelJ, DurandD.Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil.Transplantation2000; 69: 991–994.
14.
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.Transplantation1996; 61: 1029–1037.
15.
EasonJD, LossGE, BlazekJ, NairS, MasonAL.Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial.Liver Transpl2001; 7: 693–697.
16.
BerenguerM, PrietoM, San JuanF. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.Hepatology2002; 36: 202–210.
17.
BerenguerM, FerrellL, WatsonJ. HCV-related fibrosis progression following liver transplantation: increase in recent years.J Hepatol2000; 32: 673–684.
18.
FormanLM, LewisJD, BerlinJA, FeldmanHI, LuceyMR.The association between hepatitis C infection and survival after liver transplantation.Gastroenterology2002; 122: 889–896.
19.
GaneEJ, PortmannBC, NaoumovNV. Long-term outcome of hepatitis C infection after liver transplantation.N Engl J Med1996; 334: 815–820.
20.
BokerKHW, DalleyG, BahrMJ. Long-term outcome of hepatitis C virus infection after liver transplantation.Hepatology1997; 25: 203–210.
21.
FerayC, GigouM, SamuelD. The course of hepatitis C virus infection after liver transplantation.Hepatology1994; 20: 1137–1143.
22.
GhobrialRM, FarmerDG, BaquerizoA. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.Ann Surg1999; 229: 824–833.
23.
GhobrialRM, SteadmanR, GornbeinJ. A 10 year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients.Ann Surg2001; 234: 384–393.
24.
WiesnerR, RabkinJ, KlintmalmG. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.Liver Transpl2001; 7: 442–450.
25.
JainA, KashyapR, DemetrisAJ, EghstesadB, PokharnaR, FungJJ.A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.Liver Transpl2002; 8: 40–46.
26.
BurakKW, KremersWK, BattsKP. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.Liver Transpl2002; 8: 362–369.
27.
NelsonDR, Soldevila-PicoC, ReedA. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.Liver Transpl2001; 7: 1064–1070.
28.
GaneEJ, NaoumovNV, QianKP. A longitudinal analysis of hepatitis C virus replication following liver transplantation.Gastroenterology1996; 110: 167–177.
29.
CharltonM, SeabergE.Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.Liver Transpl Surg1999; 5(suppl): S107–S114.
30.
SheinerPA, SchwartzME, MorE. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.Hepatology1995; 21: 30–34.
31.
Wietzke-BraunP, BraunF, SattlerB, RamadoriG, RingeB.Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis c virus related cirrhosis.World J Gastroenterol2004; 10: 2213–2217.
32.
LangrehrJM, NeumannUP, LangM. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV.Transplant Proc2002; 34: 1565–1566.
33.
BreitenfeldtMK, RasenackJ, BertholdH. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation.Clin Transplant2002; 16: 130–136.
34.
AbbottKC, BucciJR, MatsumotoCS. Hepatitis C and renal transplantation in the era of modern immunosuppression.J Am Soc Nephrol2003; 14: 2908–2918.
35.
SumethkulV, IngsathitA, Leelasa-NguanP, JirasirithamS.Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: is it justified?Transplant Proc2002; 34: 3217–3219.
36.
SollingerHW.Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.Transplantation1995; 60: 225–232.
37.
GumberSC, ChopraS.Hepatitic C: a multifaceted disease.Ann Intern Med1995; 123: 615–620.
38.
Ramos-CasalsM, FontJ, IngelmoM.Prevalence and clinical significance of hepatitis C virus infection in systemic autoimmune diseases.Med Clin (Barc)2001; 116: 701–709.
39.
Ramos-CasalsM, Loustaud-RattiV, ZeherM.Hepatitits C virus and autoimmune diseases. In Ramos-CasalsM, Garcia-CarrascoM, RosasJ, CalvoJ, FontJ editors. Masson: Barcelona2005 (in press).
40.
Ramos-CasalsM, TrejoO, Garcia-CarrascoM, FontJ.Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.Rheumatology (Oxford)2003; 42: 818–828.
41.
HernándezF, BlanquerA, LinaresM, LópezA, TarinF, CerveróA.Autoimmune thrombocytopenia associated with hepatitis C virus infection.Acta Haematol1998; 99: 217–220.
42.
LinaresM, CerveróA, ColominaP. Chronic idiopathic thrombocytopenic purpura in the elderly.Acta Haematol1995; 93: 80–82.
43.
SaabS, MartinP.Hemolytic anemia and the treatment of chronic hepatitis C.J Clin Gastroenterol1999; 28: 289–290.
44.
Ramos-CasalsM, Garcia-CarrascoM, Lopez-MedranoF. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases.Medicine (Baltimore)2003; 82: 87–96.
45.
den OttolanderGJ, GratamaJW, de KoningJ, BrandA.Long-term follow-up study of 168 patients with immune thrombocytopenia: implications for therapy.Scand J Haematol1984; 32: 101–110.
46.
DiFinoSM, LachantNA, KirshnerJJ, GottliebAJ.Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy.Am J Med1980; 69: 430–442.
47.
GeorgeJN, WoolfSH, RaskobGE. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology.Blood1996; 88: 3–40.
48.
MagrinS, CraxiA, FabianoC. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment.Hepatology1994; 19: 273–279.
49.
IerardiE, RendinaM, FrancavillaR. Mycophenolate mofetil in the treatment of autoimmune HCV-associated haematological disorders showing steroid resistance or dependence.J Viral Hepat2003; 10: 390–393.
50.
TrejoO, Ramos-CasalsM, Garcia-CarrascoM. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center.Medicine (Baltimore)2001; 80: 252–262.
51.
ZuckermanE, KerenD, SlobodinG. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α.J Rheumatol2000; 27: 2172–2178.
52.
CacoubP, MaisonobeT, GatelA, ServanJ, MussetL, PietteJC.Systemic vasculitis in patients with hepatitis C.J Rheumatol2001; 28: 109–118.
53.
CacoubP, LidoveO, MaisonobeT. Interferon-α; and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.Arthritis Rheum2002; 46: 3317–3326.
54.
FerriC, MoriconiL, GremignaiG. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange.Nephron1986; 43: 246–253.
55.
KarmochkineM, BusselA, LeonA, JarrousseB, BaudelotJ, GuillevinL.Long-term plasma exchange. Analysis of indications, outcome and side effects.Ann Med Interne (Paris)1994; 145: 373–375.
56.
GrossWL.New concepts in treatment protocols for severe systemic vasculitis.Curr Opin Rheumatol1999; 11: 41–46.
CaponnettoC, RossiE, PrimaveraA.Mycophenolate mofetil: A new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection.Eur Neurol2001; 46: 53–54.
59.
MedinaF, FuentesJ, CarranzaI. Mycophenolate mofetil: a potential treatment for diffuse prolipherative lupus nephritis and chronic hepatitis C virus.Arthritis Rheum2004; 50(suppl): S415.
